comparemela.com

Latest Breaking News On - Nmrd - Page 1 : comparemela.com

Melcor Developments Ltd. Plans Quarterly Dividend of $0.11 (TSE:MRD)

Melcor Developments Ltd. (TSE:MRD – Get Free Report) declared a quarterly dividend on Tuesday, May 14th, Zacks reports. Stockholders of record on Friday, June 14th will be given a dividend of 0.11 per share on Friday, June 28th. This represents a $0.44 annualized dividend and a dividend yield of 3.77%. The ex-dividend date is Friday, […]

Canada
United-states
Melcor-developments-company-profile
Melcor-developments-ltd
Melcor-developments
Get-free-report
Melcor-developments-daily
Tse-mrd
Nmrd
Real-estate
Dividends

MRD Testing in CRC: Gaps in our Understanding and Potential Advancements

The expert panel continues the discussion with thoughts on gaps in our understanding and application of MRD testing for colorectal cancer and a look to the future, highlighting potential advancements.

Colorectal-cancer
Crc
Mrd-testing
Nmrd
Minimal-residual-disease
Ctdna
Circulating-tumor-dna
Patient-profile
Patient-case

Trajectory of CRC Treatment Landscape

The panelists provide their final thoughts, exploring the prospective treatment landscape for patients with CRC.

Colorectal-cancer
Crc
Mrd-testing
Nmrd
Minimal-residual-disease
Ctdna
Circulating-tumor-dna
Patient-profile
Patient-case

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer: Part 2

The panel continues its review of data presented on MRD testing in colorectal cancer from the INTERCEPT and COSMOS-CRC-01 studies.

Colorectal-cancer
Crc
Mrd-testing
Nmrd
Minimal-residual-disease
Ctdna
Circulating-tumor-dna
Patient-profile
Patient-case

Recent Data from INTERCEPT and COSMOS-CRC-01 in Colorectal Cancer

The panel reviews recent data on MRD testing in colorectal cancer, highlighting the INTERCEPT and COSMOS-CRC-01 studies.

Colorectal-cancer
Crc
Mrd-testing
Nmrd
Minimal-residual-disease
Ctdna
Circulating-tumor-dna
Patient-profile
Patient-case

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.